597. Targeting coagulation factor receptors - protease-activated receptors in idiopathic pulmonary fibrosis 608. Hematology journals do not sufficiently adhere to reporting guidelines: a systemati…
835. Ibrutinib-associated bleeding: pathogenesis, management adn risk reduction strategies 848. Long-term treatment of cancer-associated Thrombosis: the choice of the optimal anticoagulant 858. I…
1541. C-reative protein gene polymorphism preditct the risk of thromboboembolic stroke in patiens with atrial fibrillation a more than 10-year prospective follow-up study 1547. Assement of clinica…
873. Vasa vasorum and atherosclerosis 880. Circulating P-selection and the risk of reccurent venous thromboembolisms 884. Characterisation of five factor XI mutations 890. Calcium-binding sites…
917. CXCL4 in atherosclerosis : Possible roles in monocyte arrest and macrophage foam cell formation 919. Vascular remodelling processes cells, signals and their integration 922. Platelet intera…
977. TB-402 For the prevention of venous throboembolism in orthopaedic surgery: something new and promising or not 980. CD4 + T Cells in atherosclerosis regulation by platelets 991. The physiolo…
671. The importance of the excellence in the quality of anticoagulation control whilst taking vitamin K antagonists 674. Antithrombotic treatment in patients undergoing transcatheter aorotic valve…
Vascular complications in diabetic pregnancy Pathogenesis and management of antiphospholipid syndrome Predicting recurrences or major bleeding in women with cancer and venous thromboembolism Can…